Form 8-K · Current report
Boston Scientific 8-K, filed Oct 28, 2026
- Filed
- CIK
- 0000885725
- Accession no.
- 0000885725-26-000066
Summary
Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5% from a year earlier, with GAAP EPS of $0.40 and adjusted EPS of $0.73, and guided to full-year adjusted EPS of $3.16–$3.18 and a fourth-quarter net sales decline of about 1.0%–3.0%. CEO Mike Mahoney said the year was challenging and cited the August 2026 cybersecurity incident, while the company announced FDA clearances and a Heartflow collaboration.
Key points
- Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5% year over year, with GAAP EPS of $0.40 and adjusted EPS of $0.73.
- The company guided full-year 2026 adjusted EPS to $3.16–$3.18 and estimated fourth-quarter 2026 net sales would decline by about 1.0% to 3.0% year over year.
- It received FDA 510(k) clearances for the StoneSmart Navigator Flex Ureteral Access Sheath Set, the LithoVue Elite ureteroscope, and an expanded size offering of the SEISMIQ peripheral catheter.
- It entered a strategic collaboration with Heartflow to advance AI-powered CT-guided planning for percutaneous coronary intervention.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On October 28, 2026, Boston Scientific Corporation issued a press release announcing financial results for the third quarter ended September 30, 2026. A copy of the release is furnished with this report as Exhibit 99.1. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.